Table 1. Baseline data. Continuous data were given as mean ± standard deviation.
| Variables | Prosthesis eversion method | Traditional method | P value |
|---|---|---|---|
| Number of patients | 195 | 88 | – |
| Age (years) | 44.9±16.6 | 48.9±12.9 | 0.0461# |
| Male | 106 (54.4%) | 51 (58.0%) | 0.6068 |
| BMI | 24.5±3.4 | 24.3±4.6 | 0.6832 |
| Previous cardiac surgery | 3 (1.5%) | 1 (1.1%) | 1.0000 |
| Waiting time (hours) | 28.6±20.5 | 30.9±24.1 | 0.4094 |
| Platelet count <10^9/L | 23 (11.8%) | 13 (14.8%) | 0.5635 |
| PT (seconds) | 13.4±2.6 | 12.9±3.1 | 0.1601 |
| APTT (seconds) | 36.4±5.6 | 37.2±5.7 | 0.2696 |
| INR | 1.41±0.31 | 1.36±0.26 | 0.1886 |
| Hypertension | 186 (95.4%) | 81 (92%) | 0.2741 |
| Diabetes mellitus | 31 (15.9%) | 21 (23.9%) | 0.1352 |
| Renal insufficiency | 21 (10.8%) | 4 (4.5%) | 0.1132 |
| NYHA III-IV | 13 (6.7%) | 4 (4.5%) | 0.5964 |
| EF <50% | 7 (3.6%) | 3 (3.4%) | 1.0000 |
| Hyperlipidemia | 61 (31.3%) | 16 (18.2%) | 0.0218# |
| Antiplatelet therapy | 19 (9.7%) | 16 (18.2%) | 0.0526 |
| Lipid-lowering drugs | 43 (22.1%) | 11 (12.5%) | 0.0719 |
| β-blocker | 187 (95.9%) | 81 (92%) | 0.2495 |
| ACEI/ARB | 43 (22.1%) | 32 (36.4%) | 0.0136# |
| Calaiumchannal blocker | 55 (28.2%) | 26 (29.5%) | 0.8871 |
#, indicates P<0.05. BMI, body mass index; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; EF, ejection fraction; ACEI, Angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.